Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Presence of a complex karyotype did not affect progression-free or overall survival.
Chronic Lymphocytic Leukemia
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Familial Risks Associated With Hematologic Malignancies
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Therapy Selection in CLL
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
HLA-B27 Positivity Did Not Influence CLL, SLL Outcomes
Further studies needed to look at relevance outside of the transplant-eligible population.
After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
Improved Survival Outcomes With Ibrutinib Plus Rituximab in Chronic Lymphocytic Leukemia
Patients who received ibrutinib and rituximab had a 3-year PFS rate of 89.4%, compared with 72.9% in patients receiving chemoimmunotherapy.
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
FDA Greenlights New Rituxan Biosimilar
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Next post in Leukemia
